Q-omics provides the consensus-scored C9orf92 profile across patient tissues and cancer cell-line models. C9orf92 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, C9orf92 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, C9orf92 RNA expression shows 11,356 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, THCA, and UVM as cancer lineages where C9orf92 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C9orf92 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C9orf92 survival associations across molecular data types. C9orf92 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C9orf92 RNA expression–survival associations across cancer types. High C9orf92 expression shows unfavorable associations in LUAD, UVM, STAD, ESCA, BRCA and UCEC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for C9orf92 RNA expression.
This table summarizes C9orf92 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for C9orf92. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C9orf92 shows lower tumor expression in THCA, UCEC, KICH and BLCA and higher tumor expression in KIRC and LUAD. The THCA box plot shows higher C9orf92 RNA expression in normal versus tumor tissue (log2 FC = −1.923, t-test p < 0.001).
This table shows molecular features associated with C9orf92 in patient tissues and cancer cell lines. In patient samples, C9orf92 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C9orf92 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SKIN.
